# IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI

Study · id `cardio:ct-nct07875179` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07875179](<https://clinicaltrials.gov/study/NCT07875179>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07875179

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3300 participants.

## Technical summary

Registry record NCT07875179. Randomized; no masking; primary purpose treatment. Start 2026-09-28 (anticipated); primary completion 2028-09-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3300 participants (planned count; ClinicalTrials.gov record NCT07875179, source copy `cardio:ctgov-nct07875179-2026-10-15`, retrieved 2026-10-26)
- Planned start: 2026-09-28 (anticipated) (ClinicalTrials.gov record NCT07875179, source copy `cardio:ctgov-nct07875179-2026-10-15`, retrieved 2026-10-26)
- Primary completion: 2028-09-28 (anticipated) (ClinicalTrials.gov record NCT07875179, source copy `cardio:ctgov-nct07875179-2026-10-15`, retrieved 2026-10-26)
- Completion: 2028-09-28 (anticipated) (ClinicalTrials.gov record NCT07875179, source copy `cardio:ctgov-nct07875179-2026-10-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07875179, source copy `cardio:ctgov-nct07875179-2026-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07875179-2026-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
- Acronym: IMPROVE-STEMI
- Condition: ST Elevation Myocardial Infarction (STEMI)
- Intervention (Drug): Recombinant Streptokinase
- Lead sponsor: The Affiliated Hospital of Xuzhou Medical University
- Lead sponsor class: OTHER
- Collaborator: China Association for Disaster & Emergency Rescue Medicine
- Collaborator class: UNKNOWN
- Collaborator: Henan Singtier Pharmaceutical Co., Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: The Affiliated Hospital of Xuzhou Medical University (`cardio:org-the-affiliated-hospital-of-xuzhou-medical-university`)

## Provenance

Content hash: 0effa2a32aac45e1ff64c8b1e13f1813c52ddfea6d7cf828b803d7130c4988fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
